Beam Therapeutics (BEAM) AI Stock Analysis

• Market Cap: $2.31B
• Dividend Yield: N/A
• Average Volume (3M): 2.47M
• Price to Earnings (P/E): ―
• Beta (1Y): 2.35
• Revenue Growth: -84.07%
• EPS Growth: -157.71%
• Country: US
• Employees: 393
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -1.10
• Shares Outstanding: 101,474,945
• 10 Day Avg. Volume: 2,510,533
• 30 Day Avg. Volume: 2,473,820
• PEG Ratio: -0.03
• Price to Book (P/B): 2.78
• Price to Sales (P/S): 32.14
• P/FCF Ratio: -5.73
• Enterprise Value/Market Cap: 0.68
• Enterprise Value/Revenue: 34.04
• Enterprise Value/Gross Profit: -238.30
• Enterprise Value/Ebitda: -3.71
• 1Y Price Target: $39.25
• Price Target Upside: 69.55% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 12
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 46 Neutral
• Price Target: $24.50 ▲(5.83% Upside)

Beam Therapeutics' overall stock score is primarily impacted by its financial performance challenges, including declining revenues and negative cash flows. While technical indicators show some positive momentum, the lack of profitability and valuation concerns weigh heavily on the score.

Positive Factors

Technological Advancements

Beam's proprietary base editing technology positions it as a leader in genetic medicine, offering a durable competitive advantage in treating genetic disorders.

Low Leverage

A low debt-to-equity ratio indicates financial stability and flexibility, allowing Beam to invest in R&D and strategic initiatives without significant financial strain.

Strategic Partnerships

Partnerships provide steady revenue streams and validate Beam's technology, enhancing its market position and supporting long-term growth.

Negative Factors

Revenue Decline

Declining revenues suggest challenges in commercializing products and achieving market penetration, impacting long-term financial performance.

Negative Cash Flows

Negative cash flows limit Beam's ability to fund operations and R&D internally, potentially requiring external financing and impacting financial sustainability.

Profitability Challenges

Persistent negative profit margins highlight ongoing challenges in achieving profitability, which may affect Beam's long-term viability and investor confidence.

Beam Therapeutics Business Overview & Revenue Model

Company Description

Beam Therapeutics is a biotechnology company focused on developing precision genetic medicines using its proprietary base editing technology. The company operates in the biotechnology sector, targeting genetic diseases through innovative therapies that aim to correct genetic mutations at the single-base level. Beam's core products include various pipeline candidates designed to treat conditions such as sickle cell disease, beta-thalassemia, and other genetic disorders, leveraging its advanced editing capabilities to provide potentially curative options.

How the Company Makes Money

Beam Therapeutics generates revenue primarily through collaborations and partnerships with pharmaceutical companies and other biotech firms. These partnerships often involve licensing agreements where Beam provides access to its base editing technology in exchange for upfront payments, research funding, and milestone payments tied to the achievement of specific developmental and regulatory objectives. Additionally, the company may earn royalties on future sales of products developed using its technology. As the company advances its clinical programs and moves towards regulatory approvals, potential revenue from product commercialization could also contribute significantly to its earnings.

Beam Therapeutics Financial Statement Overview

Summary

Beam Therapeutics faces significant financial challenges, with declining revenues, persistent losses, and negative cash flows. Despite a low debt-to-equity ratio, the negative profitability metrics and cash flow issues highlight the need for strategic improvements.

Income Statement

Beam Therapeutics has experienced declining revenue growth, with a negative growth rate of -5.2% in the TTM period. The company has consistently reported negative net profit margins, with the TTM net profit margin at -6.61%. Gross profit margin has also decreased significantly from previous periods. These factors indicate challenges in achieving profitability and revenue stability.

Balance Sheet

The company's debt-to-equity ratio has improved to 0.15 in the TTM period, indicating a relatively low level of leverage. However, the return on equity remains negative at -43.15%, reflecting ongoing losses. The equity ratio is stable, suggesting a solid equity base relative to total assets, but profitability issues persist.

Cash Flow

Beam Therapeutics has negative operating and free cash flows, with a declining free cash flow growth rate of -149.2% in the TTM period. The operating cash flow to net income ratio is negative, indicating cash flow challenges. Despite a positive free cash flow to net income ratio, the overall cash flow position remains weak.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	46.00M	63.52M	377.71M	60.92M	51.84M	24.00K
Gross Profit	-6.57M	41.59M	-59.67M	38.34M	35.40M	-103.16M
EBITDA	-422.25M	-383.98M	-156.47M	-324.33M	-392.46M	-128.03M
Net Income	-414.64M	-376.74M	-132.53M	-263.59M	-341.36M	-256.42M
Balance Sheet
Total Assets	1.31B	1.10B	1.46B	1.34B	1.47B	451.68M
Cash, Cash Equivalents and Short-Term Investments	1.07B	850.74M	1.19B	1.08B	965.65M	299.67M
Total Debt	151.42M	161.43M	172.69M	179.00M	142.35M	100.23M
Total Liabilities	345.08M	370.28M	478.38M	608.24M	647.72M	206.12M
Stockholders Equity	966.00M	733.54M	981.33M	733.47M	826.74M	245.56M
Cash Flow
Free Cash Flow	-352.36M	-356.19M	-182.93M	-26.42M	-113.08M	-112.10M
Operating Cash Flow	-338.18M	-347.25M	-149.19M	22.53M	-66.27M	-95.74M
Investing Cash Flow	-103.56M	185.01M	71.84M	-461.34M	-294.14M	-100.12M
Financing Cash Flow	479.61M	7.74M	276.45M	111.59M	756.14M	322.32M

Beam Therapeutics Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 23.15
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BEAM, the sentiment is Neutral. The current price of 23.15 is below the 20-day moving average (MA) of 26.02, below the 50-day MA of 23.88, and above the 200-day MA of 21.50, indicating a neutral trend. The MACD of -0.29 indicates Positive momentum. The RSI at 42.57 is Neutral, neither overbought nor oversold. The STOCH value of 10.85 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for BEAM.

Beam Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
IMCR	63 Neutral	$1.61B	―	-5.38%	―	26.90%	62.72%
ARQT	59 Neutral	$2.94B	―	-28.17%	―	129.21%	80.35%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
BEAM	46 Neutral	$2.31B	―	-47.19%	―	-84.07%	-157.71%
DNLI	45 Neutral	$2.18B	-5.31	-39.69%	―	-100.00%	1.62%
IMVT	45 Neutral	$4.22B	―	-77.58%	―	―	-48.38%
IRON	43 Neutral	$3.22B	―	-26.36%	―	―	-22.19%

Beam Therapeutics Corporate Events

Beam Therapeutics Advances BEAM-302 Study for AATD: Key Insights for Investors

Study Overview: Beam Therapeutics, Inc. is conducting a Phase 1/2 study titled ‘A Phase 1/2 Dose-exploration and Dose-expansion Study to Evaluate the Safety and Efficacy of BEAM-302 in Adult Patients With Alpha-1 Antitrypsin Deficiency (AATD)-Associated Lung Disease and/or Liver Disease.’ The study aims to assess the safety, tolerability, pharmacokinetics/pharmacodynamics (PK/PD), and efficacy of BEAM-302, as well as to determine the optimal biological dose (OBD) for treating AATD-associated conditions.

Beam Therapeutics’ BEAM-301 Study: A Promising Step in Rare Disease Treatment

Beam Therapeutics, Inc. is conducting a Phase 1/2 study titled A Phase 1/2, Dose-Exploration Study to Evaluate the Safety and Efficacy of BEAM-301 in Patients With Glycogen Storage Disease Type Ia (GSDIa). This study aims to assess the safety, tolerability, and efficacy of BEAM-301, a novel treatment for patients with GSDIa who have specific genetic variants. The study’s significance lies in its potential to offer a new therapeutic option for this rare metabolic disorder.

Beam Therapeutics’ BEACON Trial: A New Hope for Sickle Cell Disease

Beam Therapeutics, Inc. is conducting the BEACON trial, officially titled ‘A Phase 1/2 Study Evaluating the Safety and Efficacy of a Single Dose of Autologous CD34+ Base Edited Hematopoietic Stem Cells (BEAM-101) in Patients With Sickle Cell Disease and Severe Vaso-Occlusive Crises.’ The study aims to assess the safety and efficacy of BEAM-101 in treating severe sickle cell disease, a condition with significant health impacts. This trial holds potential significance for advancing treatment options for this debilitating disease.

Beam Therapeutics Reports Q2 2025 Financial Results

Beam Therapeutics, Inc., a biotechnology company based in Cambridge, Massachusetts, is focused on developing precision genetic medicines through its base editing platform, aiming to provide life-long cures for genetic diseases. In its latest earnings report for the quarter ending June 30, 2025, Beam Therapeutics highlighted significant financial activities, including a substantial increase in marketable securities and a successful public offering that raised $470.5 million. The company reported a net loss of $102.3 million for the quarter, with operating expenses primarily driven by research and development efforts. Despite the losses, Beam’s financial position remains strong with $1.2 billion in cash, cash equivalents, and marketable securities, providing a solid foundation for future operations. Looking ahead, Beam Therapeutics is poised to continue its strategic focus on advancing its clinical trials and expanding its portfolio of genetic medicine candidates, with management expressing confidence in the company’s ability to sustain its operations and pursue growth opportunities in the biotechnology sector.